Mu and delta opioid receptors mediate opposite modulations by morphine of the spinal release of cholecystokinin-like material
暂无分享,去创建一个
M. Hamon | A. Mauborgne | S. Bourgoin | J. Benoliel | F. Cesselin | E. Collin | J. Legrand
[1] G. Pasternak,et al. An opiate-receptor gene family reunion , 1994, Trends in Neurosciences.
[2] G. Pasternak,et al. Modulation of Mu1 opioid binding by magnesium: evidence for multiple receptor conformations. , 1993, The Journal of pharmacology and experimental therapeutics.
[3] M. Hamon,et al. Opioid control of the release of calcitonin gene-related peptide-like material from the rat spinal cord in vivo , 1993, Brain Research.
[4] J. Han,et al. Accelerated expression of cholecystokinin gene in the brain of rats rendered tolerant to morphine. , 1992, Neuroreport.
[5] M. Laorden,et al. Interaction of U-50,488H with calcium channel agonists and antagonists in different cardiac tissues. , 1992, Journal of autonomic pharmacology.
[6] M. Hamon,et al. KAPPA-/MU-receptor interactions in the opioid control of the in vivo release of substance P-like material from the rat spinal cord , 1992, Neuroscience.
[7] M. Fournié-Zaluski,et al. Stimulation of δ‐Opioid Receptors Reduces the In Vivo Binding of the Cholecystokinin (CCK)‐B‐Selective Agonist [3H]pBC 264: Evidence for a Physiological Regulation of CCKergic Systems by Endogenous Enkephalins , 1992, Journal of neurochemistry.
[8] M. Hamon,et al. GABA, acting at both GABAA and GABAB receptors, inhibits the release of cholecystokinin-like material from the rat spinal cord in vitro , 1992, Brain Research.
[9] J. Levine,et al. Antinociceptive and motor effects of delta/mu and kappa/mu combinations of intrathecal opioid agonists , 1992, Pain.
[10] M. Hamon,et al. Opioid Control of the In Vitro Release of Cholecystokinin‐Like Material from the Rat Substantia Nigra , 1992, Journal of neurochemistry.
[11] M. Hamon,et al. Cholecystokinin (CCK)-like material and CCK mRNA levels in the rat brain and spinal cord after acute or repeated morphine treatment , 1992, Neuropeptides.
[12] M. Hamon,et al. к-Opioid receptor stimulation abolishes μ- but not δ-mediated inhibitory control of spinal Met-enkephalin release , 1992, Neuroscience Letters.
[13] D. Mayer,et al. Spinal co-administration of cholecystokinin antagonists with morphine prevents the development of opioid tolerance , 1991, Pain.
[14] H. Mosberg,et al. Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin and [D-Ala2]deltorphin II in mice: evidence for delta receptor subtypes. , 1991, The Journal of pharmacology and experimental therapeutics.
[15] K. Omote,et al. δ receptor involvement in morphine suppression of noxiously evoked activity of spinal WDR neurons in cats , 1991, Brain Research.
[16] P. Portoghese,et al. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. , 1991, The Journal of pharmacology and experimental therapeutics.
[17] L. Negri,et al. Evidence for two subtypes of δ opioid receptors in rat brain , 1991 .
[18] P. Contreras,et al. Evaluation of U-50,488H analogs for neuroprotective activity in the gerbil , 1991, Brain Research.
[19] M. Hamon,et al. Differential inhibitory/stimulatory modulation of spinal CCK release by μ and δ opioid agonists, and selective blockade of μ-dependent inhibition by κ receptor stimulation , 1991, Neuroscience Letters.
[20] J. Benoliel,et al. Cholecystokinin-like immunoreactivity in the rat spinal cord: Effects of thoracic transection , 1991, Brain Research Bulletin.
[21] A. Dickenson,et al. Electrophysiologic studies on the spinal antinociceptive action of kappa opioid agonists in the adult and 21-day-old rat. , 1991, The Journal of pharmacology and experimental therapeutics.
[22] R. Traub,et al. Effects of spinal kappa-opioid receptor agonists on the responsiveness of nociceptive superficial dorsal horn neurons , 1991, Pain.
[23] H. Mosberg,et al. Opioid δ receptor subtypes are associated with different potassium channels , 1991 .
[24] J. Benoliel,et al. Cholecystokinin-like immunoreactivity in the dorsal horn of the rat spinal cord: an attempt to analyse contradictory results between immunocytochemistry and radioimmunoassay , 1990, Neuropeptides.
[25] C. Alzheimer,et al. Nonopioid actions of the kappa-opioid receptor agonists, U 50488H and U 69593 on electrophysiologic properties of hippocampal CA3 neurons in vitro. , 1990, The Journal of pharmacology and experimental therapeutics.
[26] A. Carayon,et al. Regional Distribution of Calcitonin Gene‐Related Peptide‐, Substance P‐, Cholecystokinin‐, Met5‐Enkephalin‐, and Dynorphin A (1–8)‐Like Materials in the Spinal Cord and Dorsal Root Ganglia of Adult Rats: Effects of Dorsal Rhizotomy and Neonatal Capsaicin , 1990, Journal of neurochemistry.
[27] T. Hökfelt,et al. PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[28] G. Simonnet,et al. Differential interactions of cholecystokinin and FLFQPQRF-NH2 with μ and δ opioid antinociception in the rat spinal cord , 1990, Neuropeptides.
[29] P. Contreras,et al. Inhibition of potassium-evoked release of cholecystokinin from rat caudate-putamen, cerebral cortex and hippocampus incubated in vitro by phencyclidine and related compounds , 1990, Brain Research.
[30] J. Fujimoto,et al. Spinal dynorphin A (1–17): Possible mediator of antianalgesic action , 1990, Neuropharmacology.
[31] D. Mayer,et al. Chronic administration of cholecystokinin antagonists reverses the enhancement of spinal morphine analgesia induced by acute pretreatment , 1990, Brain Research.
[32] G. Pasternak,et al. Proglumide selectively potentiates supraspinal μ1 opioid analgesia in mice , 1990, Neuropharmacology.
[33] L. Tseng,et al. Differential effects of sulfated cholecystokinin octapeptide and proglumide injected intrathecally on antinociception induced by beta-endorphin and morphine administered intracerebroventricularly in mice. , 1990, European journal of pharmacology.
[34] D. Zimmerman,et al. Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents. , 1990, Journal of medicinal chemistry.
[35] S. Iversen,et al. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. , 1990, European journal of pharmacology.
[36] N. Baber,et al. The role of CCK, caerulein, and CCK antagonists in nociception , 1989, Pain.
[37] A. Takemori,et al. Indirect involvement of delta opioid receptors in cholecystokinin octapeptide-induced analgesia in mice. , 1989, The Journal of pharmacology and experimental therapeutics.
[38] R. Rodgers,et al. Differential effects of the CCK antagonist, MK-329, on analgesia induced by morphine, social conflict (opioid) and defeat experience (non-opioid) in male mice , 1989, Neuropharmacology.
[39] M. Sacristán,et al. In vivo release of CCK‐8 from the dorsal horn of the rat: Inhibition by DAGOL , 1989, FEBS letters.
[40] R. Freidinger. Cholecystokinin and gastrin antagonists , 1989, Medicinal research reviews.
[41] V. Hruby,et al. [3H]-[H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2] ([3H]CTOP), a potent and highly selective peptide for mu opioid receptors in rat brain. , 1989, The Journal of pharmacology and experimental therapeutics.
[42] J. Liebman,et al. Antagonism of morphine analgesia by CCK-8-S does not extend to all assays nor all opiate analgesics , 1988, Peptides.
[43] M. Rattray,et al. The novel CCK antagonist L364,718 abolished caerulein- but potentiates morphine-induced antinociception. , 1988, European journal of pharmacology.
[44] P. Portoghese,et al. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. , 1988, The Journal of pharmacology and experimental therapeutics.
[45] R. Zukin,et al. Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa 1 and kappa 2 opioid receptors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[46] S. Iversen,et al. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. , 1988, European journal of pharmacology.
[47] D. Menétrey,et al. Neuropeptides in long ascending spinal tract cells in the rat: Evidence for parallel processing of ascending information , 1988, Neuroscience.
[48] P. Portoghese,et al. Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist , 1988 .
[49] W. Zieglgänsberger,et al. Dynorphin1–17 reduces the inhibitory actions of μ-and δ-selective opioid agonists in cortical neurons of the rat in vivo , 1988, Neuroscience Letters.
[50] P. Portoghese,et al. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice. , 1987, The Journal of pharmacology and experimental therapeutics.
[51] R. Hill,et al. CCK 8 analgesia and hyperalgesia after intrathecal administration in the rat: Comparison with CCK-related peptides , 1987, Neuropeptides.
[52] P. Mantegazza,et al. Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin , 1987, Brain Research.
[53] R. Hill,et al. Antinociceptive action of cholecystokinin octapeptide (CCK 8) and related peptides in rats and mice: Effects of naloxone and peptidase inhibitors , 1987, Neuropharmacology.
[54] A. Dickenson,et al. Antagonism of μ-opioid receptor-mediated inhibitions of nociceptive neurones by U50488H and dynorphin A1–13 in the rat dorsal horn , 1987, Neuroscience Letters.
[55] M. Hamon,et al. Opposite Effects of δ and μ Opioid Receptor Agonists on the In Vitro Release of Substance P‐Like Material from the Rat Spinal Cord , 1987 .
[56] J. Besson,et al. Peripheral and spinal mechanisms of nociception. , 1987, Physiological reviews.
[57] J. Liebman,et al. Antinociceptive profile of sulfated CCK-8 Comparison with CCK-4, unsulfated CCK-8 and other neuropeptides , 1986, Neuropharmacology.
[58] L. Watkins,et al. Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide , 1985, Brain Research.
[59] L. Watkins,et al. Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates , 1985, Brain Research.
[60] S. Itoh,et al. Potentiation of β-endorphin effects by proglumide in rats , 1985 .
[61] G. Tramu,et al. Cholecystokinin-like immunoreactivity in the dorsal horn of the spinal cord of the rat: A light and electron microscopic study , 1984, Neuroscience.
[62] M. Iadarola,et al. Proglumide prevents and curtails acute tolerance to morphine in rats , 1984, Neuropharmacology.
[63] R. Maciewicz,et al. Edinger-Westphal nucleus: cholecystokinin immunocytochemistry and projections to spinal cord and trigeminal nucleus in the cat , 1984, Brain Research.
[64] L. Watkins,et al. Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. , 1984, Science.
[65] B. Roques,et al. Deltakephalin, Tyr-D-Thr-Gly-Phe-Leu-Thr: a new highly potent and fully specific agonist for opiate delta-receptors. , 1983, Biochemical and biophysical research communications.
[66] L. Watkins,et al. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. , 1983, Science.
[67] J. Morley,et al. Selective antagonists at the opiate delta-receptor. , 1982, Life sciences.
[68] V. Go,et al. Studies on the location and release of cholecystokinin and vasoactive intestinal peptide in rat and cat spinal cord , 1982, Brain Research.
[69] S. Itoh,et al. Caerulein and cholecystokinin suppress β-endorphin-induced analgesia in the rat , 1982 .
[70] H. Loh,et al. Possible regulatory role of dynorphin on morphine- and beta-endorphin-induced analgesia. , 1981, The Journal of pharmacology and experimental therapeutics.
[71] G. Zetler,et al. Antinociceptive effect of centrally administered caerulein and cholecystokinin octapeptide (CCK-8)☆ , 1981 .
[72] B. Morgan,et al. Analogues of β-LPH61–64 posessing selective agonist activity at μ-opiate receptors , 1981 .
[73] G. Zetler. Analgesia and ptosis caused by caerulein and cholecystokinin octapeptide (CCK-8) , 1980, Neuropharmacology.